おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Aldeyra Therapeutics
company
About
Aldeyra Therapeutics develops next-generation medicines to improve the lives of patients with immune-mediated diseases.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $60M
- Industries
- Biotechnology,Developer Platform,Health Care,Therapeutics
- Founded date
- Jan 1, 2004
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$60M
Aldeyra Therapeutics has raised a total of
$60M
in funding over 2 rounds. Their latest funding was raised on
Mar 26, 2019 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 26, 2019 | Post-IPO Debt | $60M | 1 |
Hercules Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Aldeyra Therapeutics is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
